Bulk dex bill passes house
This article was originally published in The Tan Sheet
Executive Summary
The House passed Michigan Republican Fred Upton's legislation, H.R. 970, to crack down on the bulk sale of dextromethorphan and prevent its abuse. "The Dextromethorphan Distribution Act of 2007" makes it illegal to sell unfinished DXM to any person or company not registered with FDA. The Senate received the bill Oct. 16 and referred it to the Health Committee. A similar bill passed in December 2006, but the Senate did not act on it. Upton recently called on the Senate to pass the measure (1"The Tan Sheet" Oct. 1, 2007, p. 5). The bill is endorsed by the American Pharmacists Association, Consumer Healthcare Products Association, Food Marketing Institute, National Association of Chain Drug Stores and The Partnership for a Drug-Free America...
You may also be interested in...
House DXM Bill Sponsor Expects Senate To Approve Measure This Year
Michigan Congressman Fred Upton says he expects to see a bill to restrict online sales of bulk dextromethorphan to entities registered with FDA pass this year
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip